Learning the lessons of antitumour necrosis factor therapy-associated psoriasis

Canadian Journal of Gastroenterology

Volumn 23, Issue 10, 2009, Pages 674-676

  Shale, Matt ^a   Ghosh, Subrata ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Adverse effects; Antitumour necrosis factor antibodies; Biological therapy; Psoriasis

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; AUTOANTIBODY; ETANERCEPT; INFLIXIMAB; RECOMBINANT ALPHA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ANKYLOSING SPONDYLITIS; ANTIBODY PRODUCTION; AUTOIMMUNITY; CHLAMYDIA TRACHOMATIS; CROHN DISEASE; DERMATOLOGY; DISEASE ASSOCIATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FAMILY HISTORY; HUMAN; INDIVIDUALIZATION; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; NOTE; PATIENT REFERRAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SKIN BIOPSY; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; CHLAMYDIA INFECTIONS; CROHN DISEASE; HUMANS; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70449702046     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/514618     Document Type: Note

References (27)

1. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-630
2. Fidder HH, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: A single center cohort study. Gut 2009;58:501-508
3. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929-936
4. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-368 (Pubitemid 41132340)
5. Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 2008;57:1639-1641
6. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent. N Engl J Med 2001;345:1098-1104 (Pubitemid 34940777)
7. Verea MM, Del Pozo J, Yebra-Pimentel MT, et al. Psoriasiform eruption induced by infliximab. Ann Pharmacother 2004;38:54-57
8. Baeten D, Kruithof E, Van den Bosch F, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: A new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003;62:829-834
9. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action. Arthritis Rheum 2008;59:996-1001.
10. Wollina U, Hansel G, Koch A, et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: First 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008;9:1-14.
11. Mössner R, Thaci D, Mohr J, et al. Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: Report on five cases. Arch Dermatol Res 2008;300:101-105
12. Wendling D, Balblanc JC, Briançon D, et al. Onset or exacerbation of cutaneous psoriasis during TNF-alpha antagonist therapy. Joint Bone Spine 2008;75:315-318
13. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti- TNF-alpha therapy. Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009;68:209-215
14. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534-542 (Pubitemid 39278071)
15. Yates VM, Watkinson G, Kelman A. Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis. Br J Dermatol 1982;106:323-330 (Pubitemid 12177002)
16. Seneschal J, Lepreux S, Bouyssou-Gauthier ML, et al. Psoriasiform drug eruptions under anti-TNF treatment of arthritis are not true psoriasis. Acta Derm Venereol 2007;87:77-80. (Pubitemid 46225397)
17. Seneschal J, Lepreux S, Milpied B, Schaeverbeke T, Taïeb A. Psoriasiform eruptions during anti-TNF-alpha treatment: Psoriasis or not? Arch Dermatol 2007;143:1593-1595
18. Fry L, Baker BS. Triggering psoriasis: The role of infections and medications. Clin Dermatol 2007;25:606-615 (Pubitemid 350087607)
19. Carter JD, Gerard HC, Hudson AP. Psoriasiform lesions induced by tumour necrosis factor antagonists: A skin-deep medical conundrum. Ann Rheum Dis 2008;67;1181-1183
20. Inman RD, Chiu B. Early cytokine profiles in the joint define pathogen clearance and severity of arthritis in Chlamydia-induced arthritis in rats. Arthritis Rheum 2006;54:499-507.
21. Cope A, Ettinger R, McDevitt H. The role of TNFa and related cytokines in the development and function of the autoreactive T cell repertoire. Res Immunol 1997;148:307-312 (Pubitemid 27435914)
22. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 2005;102:3372-3377 (Pubitemid 40328052)
23. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005;202:135-143 (Pubitemid 41002916)
24. Taylor C, Burns D, Wiselka M. Extensive psoriasis induced by interferon alpha treatment for chronic hepatitis C. Postgrad Med J 2000;76:365-367
25. Ketikoglou I, Karatapanis S, Elefsiniotis I, Kafiri G, Moulakakis A. Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. Eur J Dermatol 2005;15:107-109 (Pubitemid 40434638)
26. de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143:223-231 (Pubitemid 46294587)
27. Michaelsson G, Kajermo U, Michaelsson A, Hagforsen E. Infliximab can precipitate as well as worsen palmoplantar pustulosis: Possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct? Br J Dermatol 2005;153:1243-1244